Phuturdex › Diseases › Connective tissue disease
Drugs in development · updated 30 October 2026
Connective tissue disease: drugs in development
As of 30 October 2026 there are 22 active clinical trials (recruiting or ongoing, phases I–III) on 21 drugs for connective tissue disease. 12 are experimental, that is not yet approved in the United States.
Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.
Sign in free →Experimental drugs
Not yet approved by the US FDA for any indication.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| Cenerimod | III | 3 | NCT05648500 |
| BMS-986278 | III | 1 | NCT06025578 |
| GNR-055 | II–III | 1 | NCT05208281 |
| LitifilimabBIIB059 | III | 1 | NCT05352919 |
| Ralinepag | III | 1 | NCT03683186 |
| ADSC01 | I–II | 1 | NCT06574581 |
| Afimetoran | II | 1 | NCT04895696 |
| Envudeucitinib | II | 1 | NCT05966480 |
| Oral Ifetroban | II | 1 | NCT02682511 |
| Telitacicept | II | 1 | NCT05998759 |
| BMS-986515 | I | 1 | NCT07115745 |
| GSK4527363 | I | 1 | NCT06576271 |
Sorted by most advanced phase and number of active trials.
Approved drugs in new trials
Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| BelimumabBenlysta® | III | 3 | NCT06716606 |
| DeucravacitinibBMS-986165, Sotyktu® | III | 2 | NCT05617677 |
| Autologous cultured chondrocytes on porcine collagen membrane | III | 1 | NCT06915233 |
| AvatrombopagDoptelet Sprinkle®, Doptelet® | II | 1 | NCT04993885 |
| MethoxsalenUvadex, Oxsoralen-Ultra® | II | 1 | NCT04986605 |
| CyclophosphamideCyclophosphamid, Cytoxan | I | 1 | NCT07115745 |
| FludarabineFludara, FLUDARABIN | I | 1 | NCT07115745 |
| TocilizumabTociluzumab, Avtozma | I | 1 | NCT07115745 |
| TreprostinilTyvaso Dpi®, Yutrepia® | Early I | 1 | NCT07837830 |
Sorted by most advanced phase and number of active trials.
All 21 drugs, with the details
In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.
Open in Phuturdex →Specific forms
- Systemic lupus erythematosus 178 drugs
- Rheumatoid arthritis 130 drugs
- Systemic scleroderma 77 drugs
- Lupus nephritis 64 drugs
- Autoimmune disease 94 drugs
- Myositis 42 drugs
- Sjogren's Syndrome 29 drugs
- Diffuse scleroderma 39 drugs
- Dermatomyositis 52 drugs
- Arthritis, Juvenile 39 drugs
- Cutaneous lupus erythematosus 17 drugs
- Anti-neutrophil cytoplasmic antibody-associated vasculitis 35 drugs
Broader categories
- Skin and connective tissue diseases 3 drugs
- Respiratory disease 57 drugs
- Immune System Diseases 54 drugs
- Lung disease 104 drugs
- Autoimmune disease 94 drugs
- Hematologic Diseases 57 drugs
Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: Wikidata; NLM MeSH term: D003240 “Connective Tissue Diseases”.